CatherineC(Choy)SmithMD

Hematologic Oncology

Assistant Professor, Medicine, UCSF School of Medicine

Dr. Smith is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

Office
1600 Divisadero St
San Francisco, CA 94143
Phone+1 415-353-2421

Fax+1 415-353-2467

University of California (San Francisco)Fellowship, Hematology and Medical Oncology, 2006 - 2009
Brigham and Women's HospitalResidency, Internal Medicine, 2002 - 2005
Duke University School of MedicineClass of 2002

CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012-2013

PubMed

166 citations
Reactogenicity and immunogenicity after a late second dose or a third dose of ChAdOx1 nCoV-19 in the UK: a substudy of two randomised controlled trials (COV001 and COV...
Amy Flaxman, N G Marchevsky, D Jenkin, J Aboagye, Parvinder K. Aley
Lancet. 2021-09-11
1 citations
Correction to: Pharmacokinetic Profile of Gilteritinib: A Novel FLT-3 Tyrosine Kinase Inhibitor.
Angela Joubert James, Catherine C. Smith, Mark R. Litzow, Alexander E. Perl, Jessica K. Altman
Clinical Pharmacokinetics. 2021-07-23
6 citations
Recurrent Mutations in Cyclin D3 Confer Clinical Resistance to FLT3 Inhibitors in Acute Myeloid Leukemia
Catherine C. Smith, Aaron D. Viny, Evan Massi, Cyriac Kandoth, Nicholas D. Socci
Clinical Cancer Research. 2021-07-15

Abstracts/Posters

Combined Single-Cell DNA Genotyping and Protein Quantification (DAb-seq) in Acute Myeloid Leukemias Reveals Distinct Immunophenotypic Subsets Among Pathogenic Clones
Catherine C. Smith, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Single Cell Sequencing Reveals Evolution of Tumor Heterogeneity of Acute Myeloid Leukemia on Quizartinib
Catherine C. Smith, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Direct Oral Anticoagulant Use and Outcomes in Patients with High and Intermediate Risk BCR-ABL-Negative Myeloproliferative Neoplasms
Catherine C. Smith, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019

Lectures

Therapy of Acute Myeloid Leukemia: Adapting to Change
61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019

$Astellas Presents New Data on XOSPATA® (Gilteritinib) in FLT3 Mutation-Positive Relapsed/Refractory Acute Myeloid Leukemia at the 2019 American Society of Hematology Annual Meeting$
Astellas Presents New Data on XOSPATA® (Gilteritinib) in FLT3 Mutation-Positive Relapsed/Refractory Acute Myeloid Leukemia at the 2019 American Society of Hematology Annual MeetingDecember 2nd, 2019